Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C

Journal of Viral Hepatitis

Volumn 19, Issue SUPPL. 1, 2012, Pages 37-41

  Rumi, M ^a   Aghemo, A ^a   Prati, G M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

hepatitis C virus; pegylated interferon; safety; sustained virological response

Indexed keywords

INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANTIVIRAL ACTIVITY; ARTICLE; BONE MARROW TOXICITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG HALF LIFE; EVIDENCE BASED MEDICINE; HEPATITIS C; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HALF-LIFE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84855674072     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01525.x     Document Type: Article

References (37)

1. Samuel CE,. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14 (4): 778-809. (Pubitemid 32979631)
2. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4 (1): 63-68. (Pubitemid 36104710)
3. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315 (25): 1575-1758.
4. Hoofnagle JH,. Therapy of acute and chronic viral hepatitis 1994. Adv Intern Med 1994; 39: 241-475.
5. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352 (9138): 1426-1432. (Pubitemid 28510876)
6. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339 (21): 1485-1492. (Pubitemid 28543496)
7. Caliceti P,. Pharmacokinetics of pegylated interferons: what is misleading? Dig Liver Dis 2004; 36 (Suppl. 3): S334-S339. (Pubitemid 41070571)
8. Harris JM, Martin NE, Modi M,. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40 (7): 539-551. (Pubitemid 32738660)
9. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha-2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Clin Pharmacol Ther 2000; 68 (5): 556-567.
10. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 KDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001; 12 (2): 195-202. (Pubitemid 32235471)
11. Foster GR,. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004; 20 (8): 825-830. (Pubitemid 39424889)
12. Silva M, Poo J, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon α-2b and peginterferon α-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006; 45 (2): 204-213.
13. Grace M, Youngster S, Gitlin G, et al. Structural and biologic characterization of pegylated recombinant IFN-alpha2b. J Interferon Cytokine Res 2001; 21 (12): 1103-1115. (Pubitemid 34121056)
14. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965. (Pubitemid 32913521)
15. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347 (13): 975-982.
16. Garattini S, Bertele' V,. Ethics in clinical research. J Hepatol 2009; 51 (4): 792-797.
17. Witthoeft T, Hueppe D, John C, et al. Efficacy and tolerability of peginterferon α-2a or α-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study. J Viral Hepat 2010; 17 (7): 459-468.
18. Almasio PL, Cavalletto L, Chemello L, et al. Efficacy of Peg-IFN α-2b vs Peg-IFN α-2a + ribavirin regimens in treatment-naive chronic HCV patients: a cumulative meta-analysis of retrospective data from 6 clinic sites. Hepatology 2005; 42 (Suppl): A671.
19. Manos M, Shvachko V, Murphy R, et al. Determinants of sustained viral response (SVR) in patients receiving Peg-Interferon/Ribavirin therapy for hepatitis C: results from a diverse managed care population. 13th Annual International Symposium on Viral Hepatitis and Liver diseases, 23 March 2009.
20. Backus LI, Boothroyd DB, Phillips BR, Mole LA,. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46 (1): 37-47. (Pubitemid 47171919)
21. Thuy PT, Dat HT,. Comparison between the two Peginterferons α in the treatment of chronic hepatitis C. Hepatology 2007; 4 (Suppl. 1): 387A-388A.
22. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon α-2b or α-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361 (6): 580-593.
23. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon α-2a plus ribavirin is more effective than peginterferon α-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138 (1): 116-122.
24. Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138 (1): 108-115.
25. Rumi MG,. Pegylated interferon α2b versus pegylated interferon alpha2a for chronic hepatitis C: the unreached goal of superiority. J Hepatol 2009; 51 (6): 1097-1099.
26. Craxì A,. PEG IFN α-2a vs. α-2b: and the winner is.? J Hepatol 2010; 52 (1): 133-135.
27. Schulze Zur Wiesch J, Lohse AW,. Results of the IDEAL trial: "Mirror, mirror on the wall. which's the fairest peg-interferon of them all?". Hepatology 2009; 50 (6): 2034-2037.
28. Aghemo A, Colombo M,. Peginterferon α-2b versus peginterferon α-2a with ribavirin for the treatment of chronic hepatitis C: the pursuit of an ideal. Gastroenterology 2010; 138 (1): 386-389.
29. Hadziyannis SJ, Sette Jr H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140 (5): 346-355.
30. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262): 399-401.
31. Jacobson IM, Brown Jr RS, Freilich B, et al. Peginterferon α-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46 (4): 971-981. (Pubitemid 350144761)
32. Awad T, Thorlund K, Hauser G, et al. PegInterferon-α2a is associated with higher sustained virological than PegInterferon-α2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010; 51 (4): 1176-1184.
33. Sinha S, Gulur P, Patel V, Hage-Nassar G, Tenner S,. A randomized prospective clinical trial comparing pegylated interferon alpha 2a / ribavirin versus pegylated interferon alpha 2b / ribavirin in the treatment of chronic hepatitis C. Am J Gastroenterol 2004; 99: 237.
34. Yenice N, Mehtap O, Gumrah M, Arican N,. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol 2006; 17: 94-98. (Pubitemid 46567826)
35. Scotto G, Fazio V, Fornabaio C, et al. Peg-interferon alpha-2a versus peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study. J Interferon Cytokine Res 2008; 28: 623-630.
36. Kolakowska A, Berok H, Wasilewski M, Horbon A,. Relevance between fibrosis and response to treatment with peginterferon alfa2a vs alfa2b with ribavirin in chronic hepatitis C genotype 3 patients. Randomized open label study. Hepatology 2008; 48: 1278.
37. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009; 49: 22-31.